RESUMO
BACKGROUND: Estrogen deficiency in women and high-saturated fat, high-sucrose (HFS) diets have both been recognized as risk factors for metabolic syndrome. Studies on the combined actions of these 2 detrimental factors on the bone in females are limited. OBJECTIVE: We sought to determine the interactive actions of estrogen deficiency and an HFS diet on bone properties and to investigate the underlying mechanisms. METHODS: Six-month-old Sprague Dawley sham or ovariectomized (OVX) rats were pair fed the same amount of either a low-saturated-fat, low-sucrose (LFS) diet (13% fat calories; 15% sucrose calories) or an HFS diet (42% fat calories; 30% sucrose calories) for 12 wk. Blood, liver, and bone were collected for correspondent parameters measurement. RESULTS: Ovariectomy decreased bone mineral density in the tibia head (TH) by 62% and the femoral end (FE) by 49% (P < 0.0001). The HFS diet aggravated bone loss in OVX rats by an additional 41% in the TH and 37% in the FE (P < 0.05). Bone loss in the HFS-OVX rats was accompanied by increased urinary deoxypyridinoline concentrations by 28% (P < 0.05). The HFS diet induced cathepsin K by 145% but reduced osteoprotegerin mRNA expression at the FE of the HFS-sham rats by 71% (P < 0.05). Ovariectomy significantly increased peroxisome proliferator-activated receptor γ mRNA expression by 136% and 170% at the FE of the LFS- and HFS-OVX rats, respectively (P < 0.05). The HFS diet aggravated ovariectomy-induced lipid deposition and oxidative stress (OS) in rat livers (P < 0.05). Trabecular bone mineral density at the FE was negatively correlated with rat liver malondialdehyde concentrations (R(2) = 0.39; P < 0.01). CONCLUSIONS: The detrimental actions of the HFS diet and ovariectomy on bone properties in rats occurred mainly in cancellous bones and were characterized by a high degree of bone resorption and alterations in OS.
Assuntos
Reabsorção Óssea/fisiopatologia , Dieta Hiperlipídica/efeitos adversos , Sacarose Alimentar/administração & dosagem , Ácidos Graxos/administração & dosagem , Aminoácidos/sangue , Aminoácidos/urina , Animais , Biomarcadores/sangue , Reabsorção Óssea/sangue , Cálcio/sangue , Cálcio/urina , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Sacarose Alimentar/efeitos adversos , Ingestão de Energia , Estrogênios/sangue , Estrogênios/deficiência , Ácidos Graxos/efeitos adversos , Feminino , Modelos Lineares , Osteocalcina/sangue , Osteocalcina/urina , Ovariectomia , Fósforo/sangue , Fósforo/urina , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Triglicerídeos/sangueRESUMO
OBJECTIVES: To evaluate the effects of a combined oral contraceptive (COC) containing dienogest/oestradiol valerate (DNG/E2V) on bone mineral density (BMD) and on serum and urinary bone turnover markers in young, healthy, fertile women. METHODS: At baseline and after three and six months of intake of the aforementioned COC, serum and urinary calcium, osteocalcin, urinary pyridinoline (PYD), and deoxypyridinoline (D-PYD) of 30 women aged 21 to 34 years were measured. At baseline and after six months, lumbar bone mineral density was determined by dual-energy X-ray absorptiometry (DEXA). RESULTS: Urinary levels of PYD and D-PYD were significantly lower at three and six months in comparison with basal values (p < 0.05). Serum calcium levels showed an increasing trend, which reached statistical significance after six months in comparison with basal values while urinary levels of calcium did not vary significantly. Serum osteocalcin levels were somewhat, but not significantly, lower during pill use in comparison with basal values. After six months, spinal BMD values did not differ significantly from basal values. CONCLUSIONS: The DNG/E2V COC has no short-term adverse effect on bone turnover markers. No significant change in BMD was observed after six months of use of that pill.
Assuntos
Densidade Óssea/efeitos dos fármacos , Osso e Ossos/metabolismo , Anticoncepcionais Orais Combinados/farmacologia , Anticoncepcionais Orais Hormonais/farmacologia , Estradiol/farmacologia , Nandrolona/análogos & derivados , Absorciometria de Fóton , Adulto , Aminoácidos/urina , Cálcio/sangue , Cálcio/urina , Feminino , Humanos , Vértebras Lombares/diagnóstico por imagem , Nandrolona/farmacologia , Osteocalcina/sangue , Osteocalcina/urina , Fatores de Tempo , Adulto JovemRESUMO
OBJECTIVES: This study evaluated the influence of oestrogen deficiency and its therapies on bone tissue around osseointegrated implants. METHODS: Implants were placed in 66 female rats tibiae. The animals were assigned into five groups: control (CTL), sham, ovariectomy (OVX), oestrogen (EST), and alendronate (ALE). While CTL was sacrificed 60 days after implant placement, other groups were subjected to ovariectomy or sham surgery according to group and euthanized after 90 days. Blood and urine samples were collected at sacrifice day for osteocalcin (OCN) and deoxypyridinoline (DPD) quantification. Densitometry of femur and lumbar vertebrae was performed in order to evaluate rats' skeletal impairment. Non-decalcified sections were referred to fluorescent and light microscopy for analyses of mineral apposition rate (MAR), eroded and osteoclastic surfaces, bone-to-implant contact (BIC), and bone area fraction occupancy (BAFO). RESULTS: Results from the OVX group showed significantly lower bone mineral density (BMD), BIC, BAFO, and MAR, while OCN, deoxipiridinoline, eroded surface and ostecoclastic surface were increased compared with the other groups of the study. ALE reduced OCN and DPD concentrations, MAR, osteoclastic and eroded surfaces, and no difference was in BIC and BAFO relative to SHAM. EST and CTL showed similar results to SHAM for measurements. CONCLUSIONS: Oestrogen deficiency exerted a negative influence on bone tissue around implants, while oestrogen replacement therapy and alendronate were effective against its effects. Although alendronate therapy maintained the quantity of bone around implants, studies evaluating bone turnover kinetics are warranted.
Assuntos
Alendronato/uso terapêutico , Conservadores da Densidade Óssea/uso terapêutico , Implantes Dentários , Materiais Dentários , Estradiol/uso terapêutico , Terapia de Reposição de Estrogênios , Osseointegração/efeitos dos fármacos , Osteoporose/prevenção & controle , Ovariectomia , Tíbia/efeitos dos fármacos , Titânio , Absorciometria de Fóton , Aminoácidos/sangue , Aminoácidos/urina , Animais , Biomarcadores/sangue , Biomarcadores/urina , Densidade Óssea/efeitos dos fármacos , Reabsorção Óssea/patologia , Reabsorção Óssea/prevenção & controle , Materiais Dentários/química , Modelos Animais de Doenças , Feminino , Fêmur/efeitos dos fármacos , Vértebras Lombares/efeitos dos fármacos , Osteocalcina/sangue , Osteocalcina/urina , Osteoclastos/patologia , Osteogênese/efeitos dos fármacos , Distribuição Aleatória , Ratos , Ratos Wistar , Tíbia/patologia , Tíbia/cirurgia , Titânio/químicaRESUMO
The authors present an assessment of bone structure condition in children with acute leukemia. The changes in the collagen molecule, amino acid composition of urine and proteins reparation processes were revealed. Calcium phosphate excretion in the patients urine were increased. The serum osteocalcin level and colony formation efficiency of bone marrow fibroblasts in acute leukemia patients are lower than in control group. In the initial period of the disease 32% of patients have disturbancies in their endocrine status. The bone structure violation is combined with unfavorable disease outcome. The effectiveness of the treatment and prevention steps in acute leukemia patients depends on the leukemic process stage.
Assuntos
Aminoácidos , Osso e Ossos/patologia , Colágeno/química , Raios gama/efeitos adversos , Leucemia , Doença Aguda , Adolescente , Aminoácidos/sangue , Aminoácidos/urina , Medula Óssea/metabolismo , Medula Óssea/patologia , Osso e Ossos/metabolismo , Osso e Ossos/efeitos da radiação , Fosfatos de Cálcio/urina , Estudos de Casos e Controles , Acidente Nuclear de Chernobyl , Criança , Pré-Escolar , Colágeno/metabolismo , Ensaio de Unidades Formadoras de Colônias , Feminino , Fibroblastos/metabolismo , Fibroblastos/patologia , Humanos , Lactente , Leucemia/sangue , Leucemia/etiologia , Leucemia/patologia , Leucemia/urina , Masculino , Estadiamento de Neoplasias , Osteocalcina/urina , Doses de Radiação , UcrâniaRESUMO
N-methyl-D-aspartate (NMDA) receptors (NMDAR) are tetrameric amino acid receptors that act as membrane calcium channels. The presence of the receptor has been detected in the principal organs responsible for calcium homeostasis (kidney, bone, and parathyroid gland), pointing to a possible role in mineral metabolism. The aim of this study was to test the effect of NMDAR activation in the kidney and on 1,25(OH)2D3 synthesis. We determined the presence of NMDAR subunits in HK-2 (human kidney cells) cells and proved its functionality. NMDA treatment for 4 days induced a decrease in 1α-hydroxylase levels and 1,25(OH)2D3 synthesis through the activation of the MAPK/ERK pathway in HK-2 cells. In vivo administration of NMDA for 4 days also caused a decrease in blood 1,25(OH)2D3 levels in healthy animals and an increase in blood PTH levels. This increase in PTH induced a decrease in the urinary excretion of calcium and an increase in urinary excretion of phosphorous and sodium as well as in diuresis. Bone turnover markers also increased. Animals with 5/6 nephrectomy showed low levels of renal 1α-hydroxylase as well as high levels of renal glutamate compared with healthy animals. In conclusion, NMDAR activation in the kidney causes a decrease in 1,25(OH)2D3 synthesis, which induces an increase on PTH synthesis and release. In animals with chronic kidney disease, high renal levels of glutamate could be involved in the downregulation of 1α-hydroxylase expression.
Assuntos
Ácido Glutâmico/metabolismo , Hiperparatireoidismo Secundário/etiologia , Rim/metabolismo , Oxigenases de Função Mista/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Vitamina D/análogos & derivados , Animais , Cálcio/sangue , Cálcio/urina , Linhagem Celular , Creatinina/sangue , Creatinina/urina , Feminino , Humanos , Rim/enzimologia , Masculino , Osteocalcina/sangue , Osteocalcina/urina , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Fosfatos/urina , Reação em Cadeia da Polimerase , RNA Mensageiro/química , RNA Mensageiro/genética , Ratos , Ratos Sprague-Dawley , Receptores de N-Metil-D-Aspartato/genética , Vitamina D/biossíntese , Vitamina D/metabolismoRESUMO
BACKGROUND: Micro-structural changes associated with ultra high molecular weight polyethylene particle (UHMWPE) induced osteolysis, the most frequent cause of aseptic loosening, have been intensively investigated in the mammalian calvarian model by histomorphometry and micro-computed tomography. However, little is known regarding the serological changes that occur during this process. METHODS: Serological parameters for bone metabolism [calcium, phosphate, osteocalcin (OCN), deoxypyridinoline (DPD)/creatinine, alkaline phosphatase, osteoprotegerin and receptor activator of nuclear factor-κB] were analyzed in this animal model for particle induced osteolysis. Ten C57BL/6 mice were divided at random into sham operated and UHM-WPE implanted groups. Blood and urine samples were collected prior to and at 14 days after surgery. RESULTS: Implantation of UHMWPE lead to a significant decrease in bone volume (p=0.027). Both groups (sham/UHMWPE) showed a significant increase in calcium (p=0.004/p=0.027) and phosphate (p=0.001/p=0.001), without correlation to particle implantation. Significantly higher concentrations of DPD/creatinine (p=0.034) and OCN (p=0.022) were found after implantation of UHM-WPE. In addition, parameters could not be correlated to particle induced osteolysis. CONCLUSIONS: DPD can be regarded as a valuable parameter for detecting UHMWPE induced osteolysis in the calvarian model. Further studies of serum parameters should focus on the clinical relevance in aseptic prosthetic loosening.
Assuntos
Osteólise/sangue , Osteólise/urina , Polietileno/química , Polietileno/farmacologia , Fosfatase Alcalina/sangue , Fosfatase Alcalina/urina , Aminoácidos/sangue , Aminoácidos/urina , Animais , Biomarcadores/sangue , Biomarcadores/urina , Cálcio/sangue , Cálcio/urina , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Osteocalcina/sangue , Osteocalcina/urina , Osteólise/induzido quimicamente , Osteólise/diagnóstico por imagem , Osteoprotegerina/sangue , Osteoprotegerina/urina , Fosfatos/sangue , Fosfatos/urina , Período Pós-Operatório , Período Pré-Operatório , Ligante RANK/sangue , Ligante RANK/urina , Fatores de Tempo , Microtomografia por Raio-XRESUMO
The purpose of this study was to determine the effects of a 3-month walking exercise program with ankle weights on fall-related fitness, bone metabolism, and fall-related psychological factors. Fall-related fitness was determined from strength, balance, agility, aerobic endurance, muscle mass, and fat mass measures. Bone metabolism was measured using bone density, hormones, and biochemical markers. Fall-related psychological factors included fear of falling and falls efficacy. A 2 × 2 factorial with repeated measures design was used. All subjects were community-dwelling elderly women who volunteered to participate, and randomly were assigned to either an exercise group (n = 11) or a control group (n = 10). Results revealed significant changes in upper body strength, leg strength, aerobic endurance, and body composition. Additionally, hormones and biochemical markers changed significantly over time. Trunk fat and fear of falling changed differently among the two groups. In conclusion, this study suggests that a 3-month walking exercise program with ankle weights may have positive effects on fall-related fitness, bone metabolism, and fall-related psychological factors.
Assuntos
Acidentes por Quedas/prevenção & controle , Exercício Físico , Medo , Aptidão Física , Caminhada , Absorciometria de Fóton , Idoso , Envelhecimento , Biomarcadores/análise , Composição Corporal , Densidade Óssea , Colágeno Tipo I/sangue , Estradiol/sangue , Feminino , Humanos , Força Muscular , Osteocalcina/urina , Peptídeos/sangue , Resistência Física , Inquéritos e Questionários , Testosterona/sangueRESUMO
BACKGROUND & AIMS: Nutrition is one of the most important environmental factors affecting the formation of osteopenia. The purpose of this study was to investigate the effects of dietary changes on bone formation and bone resorption markers of postmenopausal women with vertebral osteopenia. METHODS: In this study, 108 women with postmenopausal vertebral osteopenia were included. Patients were observed for a month to identify their regular nutritional status. Before intervention, blood and urine samples were taken from all patients. Then, 2-day food consumption records were taken and the patients were divided into 4 groups. Different types of diets (opposite of their regular diets) were prepared for these groups (1: control, 2: reduced-carbohydrate, 3: reduced-protein, 4: reduced-sodium) and followed for 3 months. At the end of follow-ups, blood and urine samples were taken again and changes in osteocalcin (OC) and N-terminal telopeptide (NTX) levels were examined. RESULTS: According to biochemical analysis, there was a significant decrease (p < 0,001) in OC levels in reduced protein group and an increase (p > 0,05) in reduced carbohydrate group. When NTX levels were assessed, a significant decrease (p < 0.001) in the reduced carbohydrate group and a significant increase in the reduced protein group (p < 0.05) were found. CONCLUSION: Our findings show that reduced carbohydrate diet protected whereas, reduced protein diet negatively affected bone health. Osteopenic individuals were thought to be able to improve bone health and their quality of life by early dietary intervention.
Assuntos
Doenças Ósseas Metabólicas/dietoterapia , Dieta/métodos , Pós-Menopausa/sangue , Pós-Menopausa/urina , Absorciometria de Fóton , Biomarcadores/sangue , Biomarcadores/urina , Densidade Óssea , Doenças Ósseas Metabólicas/sangue , Doenças Ósseas Metabólicas/urina , Colágeno Tipo I/sangue , Colágeno Tipo I/urina , Registros de Dieta , Dieta com Restrição de Carboidratos , Dieta com Restrição de Proteínas , Dieta Hipossódica , Feminino , Humanos , Pessoa de Meia-Idade , Estado Nutricional , Osteocalcina/sangue , Osteocalcina/urina , Peptídeos/sangue , Peptídeos/urina , Resultado do TratamentoRESUMO
OBJECTIVE: Serum osteocalcin (S-OC) is widely used as an index of bone formation. However, there is evidence that some urinary fragments of OC reflect resorption and might be useful in monitoring antiresorptive therapy. Here, we report 6-month changes in urinary midfragments of osteocalcin (U-MidOC) and other bone turnover markers in response to risedronate treatment. MATERIAL AND METHODS: The study group comprised 19 patients with postmenopausal osteoporosis, aged 49-66 years, and receiving risedronate therapy. Fifty-four premenopausal women served as controls. Osteoporosis was diagnosed by lumbal bone mineral density (BMD). Urinary osteocalcin was measured by the U-MidOC assay for midfragments. Bone formation was assessed by S-PINP and S-OC, and resorption by S-CTx-I. RESULTS: At baseline, U-MidOC was significantly correlated only with S-OC. After the 1st month of therapy, a similar decrease was observed in the values of U-MidOC and S-CTx-I, but in formation markers S-P1NP and S-OC only after three months. The rapid decrease in U-MidOC, analogous to S-CTX-I, and the different kinetics for urinary and serum OC suggest that urinary OC midfragments are more associated with resorption than S-OC. An association was also observed between the 1-month change in U-MidOC and 12-month gain in lumbar BMD. The response in U-MidOC after only the 1st month of therapy makes it a potential marker for monitoring the effect of risedronate, presumably reflecting different aspects of bone resorption than S-CTx-I does.
Assuntos
Ácido Etidrônico/análogos & derivados , Osteocalcina/urina , Osteoporose Pós-Menopausa/tratamento farmacológico , Osteoporose Pós-Menopausa/urina , Idoso , Biomarcadores/urina , Densidade Óssea/efeitos dos fármacos , Ácido Etidrônico/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade , Ácido Risedrônico , Fatores de TempoRESUMO
The purpose of the treatment of osteoporosis is to reduce fracture risk and maintain/improve quality of life (QOL). The criteria for initiating pharmacotherapy to prevent fragility fractures should be provided separately from the criteria for diagnosis of osteoporosis. In Japan, low bone mineral density (BMD), prevalent fracture, and age are established as fracture risk factors from available data. A meta-analysis conducted by the WHO assured that excessive drinking (2 units a day or more), current smoking, and a family history of hip fracture are fracture risk factors. Moreover, in WHO technical report 921, high levels of CTX, a bone resorption marker as well as uncarboxylated osteocalcin were cited as risk factors of hip fracture, which can be measured in medical practice in Japan. Pharmacotherapy should be initiated with the consideration of the above risk factors. Recent large scale of randomized control trial(RCT), followed by meta-analysis demonstrated that bisphosphonates such as alendronate and risedronate as well as raloxifene (selective estrogen receptor modulator) are top grade of drugs which prevent fragility fracture in osteoporotic patients. Now, it is possible to perform evidence-based medicine in daily medical practice. As for secondary osteoporosis, along with treatment of underlying diseases, treatment aimed at preventing bone loss is necessary in many cases. Accumulating evidence is available about increased fracture threshold in glucocorticoid- and diabetes mellitus-induced osteoporosis. Therefore, early treatment should be appropriate in these cases. In osteoporotic patients, atherosclerotic vascular calcification as well as abnormal lipid metabolism often coexists. Multiple vertebral fractures followed by kyphosis often causes functional disorders of the digestive and respiratory systems.
Assuntos
Osteoporose/terapia , Aterosclerose , Biomarcadores/urina , Densidade Óssea , Conservadores da Densidade Óssea/uso terapêutico , Colágeno Tipo I/urina , Difosfonatos/uso terapêutico , Dislipidemias , Medicina Baseada em Evidências , Fraturas Espontâneas/etiologia , Fraturas Espontâneas/prevenção & controle , Humanos , Metanálise como Assunto , Osteocalcina/urina , Osteoporose/diagnóstico , Osteoporose/etiologia , Peptídeos/urina , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de RiscoRESUMO
The relationship between daily boron intake and osteocalcin-mediated osteoporosis was studied in boron-exposed postmenopausal women. It is known that boron and osteocalcin are important in bone metabolism, however the effect of boron in bone metabolism has not been fully discovered. The study was performed on 53 postmenopausal women aged 55-60 living in parts of Balikesir, Turkey, where the subjects are naturally exposed to high (≥1â¯mg/L) or low (<1â¯mg/L) boron concentration in drinking water. 24-h urine samples were collected from all participants and creatinine clearance was detected. Boron intake levels of the subjects whose clearance levels were between 80-124â¯mL/min were measured by inductively coupled plasma-optical emission spectrometry (ICP-OES) in urine samples. Serum osteocalcin levels of the subjects were measured by osteocalcin enzyme-linked immunosorbent assay (ELISA) kit. Osteocalcin polymorphism rs1800247 was detected using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Serum osteocalcin levels in boron-exposed postmenopausal women were significantly higher than that of control group (Pâ¯≤â¯0.05) and the correlation between the serum osteocalcin level and rs1800247 polymorphism was not significant in both groups (Pâ¯>â¯0.05). The differences in the distribution of osteocalcin genotypes and alleles in postmenopausal women were not significant between the boron exposed and the control groups (Pâ¯>â¯0.05). Serum osteocalcin level in the CC genotype was significantly higher compared to the TC genotype in boron-exposed group (Pâ¯≤â¯0.05). Our study suggests that daily boron intake of 1â¯mg/L may affect bone metabolism in postmenopausal women positively.
Assuntos
Boro/metabolismo , Minerais/metabolismo , Osteocalcina/genética , Osteoporose Pós-Menopausa/genética , Polimorfismo Genético/genética , Boro/administração & dosagem , Boro/sangue , Feminino , Humanos , Pessoa de Meia-Idade , Minerais/administração & dosagem , Minerais/sangue , Osteocalcina/sangue , Osteocalcina/urina , Osteoporose Pós-Menopausa/sangue , Osteoporose Pós-Menopausa/urinaRESUMO
INTRODUCTION: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. METHODS: Thirteen postmenopausal women (>or=6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. RESULTS: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. CONCLUSIONS: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.
Assuntos
Reabsorção Óssea/tratamento farmacológico , Reabsorção Óssea/metabolismo , Osso e Ossos/metabolismo , Isoflavonas/administração & dosagem , Fitoterapia , Proteínas de Soja/administração & dosagem , Adulto , Cálcio/urina , Radioisótopos de Cálcio/urina , Colágeno Tipo I/urina , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Pessoa de Meia-Idade , Osteocalcina/urina , Peptídeos/urina , Pós-MenopausaRESUMO
Recent research suggested a metabolic implication of osteocalcin (OCN) in e.g. insulin sensitivity or steroid production. We used an untargeted metabolomics approach by analyzing plasma and urine samples of 931 participants using mass spectrometry to reveal further metabolic actions of OCN. Several detected relations between OCN and metabolites were strongly linked to renal function, however, a number of associations remained significant after adjustment for renal function. Intermediates of proline catabolism were associated with OCN reflecting the implication in bone metabolism. The association to kynurenine points towards a pro-inflammatory state with increasing OCN. Inverse relations with intermediates of branch-chained amino acid metabolism suggest a link to energy metabolism. Finally, urinary surrogate markers of smoking highlight its adverse effect on OCN metabolism. In conclusion, the present study provides a read-out of metabolic actions of OCN. However, most of the associations were weak arguing for a limited role of OCN in whole-body metabolism.
Assuntos
Osteocalcina/sangue , Adulto , Idoso , Biomarcadores/sangue , Biomarcadores/urina , Diabetes Mellitus , Feminino , Alemanha , Humanos , Rim/metabolismo , Testes de Função Renal , Cinurenina/sangue , Cinurenina/urina , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Osteocalcina/urina , Fumar/sangue , Fumar/urinaRESUMO
The aim of this study was to analyze the presence of lithogenic metabolic factors in the blood and urine of patients with osteopenia versus osteoporosis. This is a cross-sectional study including 67 patients who were divided into two groups according to the presence of either osteopenia or osteoporosis as measured by bone densitometry: group 1-40 patients with osteopenia (22 men and 18 women) and group 2-27 patients with osteoporosis (13 men and 14 women). Metabolic studies were performed on the blood and urine; statistical analysis was performed comparing means and conducting linear correlation and multivariate analyses with SPSS. Statistical significance was considered to be p ≤ 0.05. The mean age of patients in group 1 was 52.9 ± 12.8 years versus 50.3 ± 11.4 in group 2; the difference was not statistically significant. In group 2, higher levels of osteocalcin, ß-crosslaps, urinary calcium, fasting urine calcium/creatinine, 24 h urine calcium/creatinine and 24 h oxaluria were observed compared to group 1. In the multivariate analysis, only the ß-crosslaps and urinary calcium were independently associated with osteoporosis. It would be advisable to determine the urinary calcium levels in patients with osteoporosis since altered levels may necessitate modifying the diagnostic and therapeutic approach to osteoporosis.
Assuntos
Doenças Ósseas Metabólicas/urina , Cálcio/urina , Hipercalciúria/urina , Osteoporose/urina , Adulto , Idoso , Doenças Ósseas Metabólicas/sangue , Doenças Ósseas Metabólicas/terapia , Osso e Ossos/metabolismo , Creatinina/sangue , Creatinina/urina , Estudos Transversais , Densitometria , Feminino , Humanos , Hipercalciúria/sangue , Masculino , Pessoa de Meia-Idade , Osteocalcina/sangue , Osteocalcina/urina , Osteoporose/sangue , Osteoporose/terapiaRESUMO
UNLABELLED: The bone phenotype of mice overexpressing MIF was studied. These mice showed decreased trabecular bone, increased bone formation rate, and increased MMP-3, -9, and -13 mRNA expression in the femora and tibias. This model provides evidence of the role played by MIF in bone remodeling and balance in vivo. INTRODUCTION: The role of macrophage migration inhibitory factor (MIF) in in vivo bone remodeling remains unelucidated. We describe disordered bone metabolism in transgenic mice overexpressing MIF. MATERIALS AND METHODS: For in vivo study, muCT, bone histomorphometry, blood and urine biochemical data, and gene expression of MIF transgenic (MIF Tg) mice and littermate wildtype (WT) mice were examined. For in vitro study, osteoclastogenesis in the co-culture of bone marrow cells and osteoblasts from MIF Tg and WT were assessed. RESULTS: muCT analyses revealed a significant reduction in the trabecular bone of distal femur in MIF Tg at 8-12 weeks of age. Histomorphometric analysis revealed increase in several measures of bone formation. Osteoclastogenesis was not influenced by the origin of bone marrow cells or osteoblasts. Urine level of deoxypyridinoline/creatinine and the mRNA levels of matrix metalloproteinase (MMP) -3, -9, and -13 in femurs were elevated in MIF Tg. CONCLUSIONS: Overexpression of MIF causes high-turnover osteoporosis in mice. The increased expression of MMPs in bone was suggested, at least in part, as one cause of this phenotype, because MMPs plays important roles for bone resorption without affecting the formation of osteoclasts. This model provides evidence of the role played by MIF in bone remodeling and balance.
Assuntos
Fatores Inibidores da Migração de Macrófagos/metabolismo , Macrófagos/metabolismo , Osteoporose/genética , Osteoporose/metabolismo , Aminoácidos/sangue , Aminoácidos/urina , Animais , Sequência de Bases , Remodelação Óssea/genética , Proteínas de Transporte/metabolismo , Células Cultivadas , Creatinina/sangue , Creatinina/urina , Modelos Animais de Doenças , Fêmur/patologia , Fatores Inibidores da Migração de Macrófagos/genética , Masculino , Glicoproteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Dados de Sequência Molecular , Osteoblastos/metabolismo , Osteocalcina/sangue , Osteocalcina/urina , Osteoporose/patologia , Ligante RANK , RNA/biossíntese , Receptor Ativador de Fator Nuclear kappa-B , Regulação para CimaRESUMO
The effects of acupuncture on bone biomechanical properties and histomorphometry in ovariectomized (OVX) rats were studied. Twenty-four 8-week-old female Sprague-Dawley rats were randomly assigned to three groups: sham, model and acupuncture. Rats in the model and acupuncture groups were ovariectomized, while those in the sham group underwent a sham operation. All rats were anesthetized and fastened for 15 minutes, and for the acupuncture group, needling on Pishu (BL20) and Shenshu (BL23) was performed. Blood and urine were collected to measure serum osteocalcin (OC) and urinary calcium, phosphorus or deoxypyridinoline (Dpd). After 16 weeks of treatment, all the rats were killed and their tibiae and femora were removed. The tibiae were used for analyses of bone histomorphometry and the femora for a three-point bending test. Acupuncture gave significant protection against ovariectomy-caused decline on femoral strength in the mechanical test, increased the trabecular bone volume and thickness, lowered the trabecular separation of tibiae and restricted the excretion of phosphorus and Dpd, while promoting the concentrations of serum osteocalcin as compared with model rats. These results seemed to indicate that acupuncture on the points of Pishu (BL20) and Shenshu (BL23) not only promoted the bone formation but also suppressed the bone resorption induced by OVX in osteoporotic rats, which suggests that it would be a potentially useful and convenient method in preventing osteoporosis.
Assuntos
Terapia por Acupuntura , Osso e Ossos/química , Osteoporose/terapia , Ovariectomia/efeitos adversos , Animais , Peso Corporal , Osso e Ossos/fisiologia , Feminino , Humanos , Tamanho do Órgão , Osteocalcina/sangue , Osteocalcina/urina , Osteoporose/metabolismo , Osteoporose/fisiopatologia , Ratos , Ratos Sprague-DawleyRESUMO
Periodontal pathogens and/or inflammatory products from periodontitis participate in the development or progression of systemic diseases. In this context, periodontitis acts as a modifying factor to systemic health, including diabetes and cardiovascular diseases. Osteoporosis is an increasingly prevalent condition in our aging population and considered a risk factor for periodontal disease, but the effect of periodontitis on systemic bone homeostasis is unknown. We thus evaluated the effects of experimental periodontitis (EP) on systemic bone loss and the influence of estrogen deficiency in this context, using a mouse model of combined periodontitis and osteoporosis. Experimental periodontitis (EP) was induced by a ligature insertion around the mandibular first molars and Porphyromonas gingivalis infection. Three-dimensional microcomputed tomographic analyses performed 48days following infection revealed that EP and ovariectomy (OVX) induced a significantly higher femoral and mandibular bone loss compared to EP or OVX alone. EP alone did not induce systemic bone loss. In addition, the EP+OVX and EP groups showed significantly higher levels of tumor necrosis factor (TNF)-α than OVX and control groups at end point. These results suggest that periodontitis could be a risk factor for systemic bone loss, especially in post-menopausal women, and warrant further clinical investigations to confirm this association and propose adapted prophylactic and curative therapies.
Assuntos
Reabsorção Óssea/etiologia , Reabsorção Óssea/patologia , Progressão da Doença , Ovariectomia/efeitos adversos , Doenças Periodontais/complicações , Doenças Periodontais/patologia , Animais , Peso Corporal , Colágeno Tipo I/sangue , Colágeno Tipo I/urina , Citocinas/sangue , Citocinas/urina , Cemento Dentário/patologia , Esmalte Dentário/patologia , Feminino , Fêmur/diagnóstico por imagem , Fêmur/patologia , Mandíbula/diagnóstico por imagem , Mandíbula/patologia , Camundongos Endogâmicos BALB C , Osteocalcina/sangue , Osteocalcina/urina , Peptídeos/sangue , Peptídeos/urina , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/urina , Microtomografia por Raio-XRESUMO
PURPOSE: To analyze the presence of phosphocalcic metabolism disorders in patients with osteopenia-osteoporosis without nephrolithiasis with respect to a control group. METHODS: A cross-sectional study was conducted in patients with osteopenia-osteoporosis without nephrolithiasis (n = 67) in lumbar spine or femur and in a control group (n = 61) with no lithiasis or bone disorders. Blood bone markers, phosphocalcic metabolism, fasting urine, 24-h urine lithogenic risk factors, and densitometry were recorded in both groups. SPSS 20.0 was used for statistical analysis. RESULTS: In comparison with the controls, significantly higher blood calcium (9.27 ± 0.36 vs. 9.57 ± 0.38, p = 0.0001), intact parathormone (45.6 ± 14.9 vs. 53.8 ± 18.9, p = 0.008), and alkaline phosphatase (61.9 ± 20.9 vs. 70.74 ± 18.9, p = 0.014) levels were found in patients with osteopenia-osteoporosis. In the 24-h urine test, citrate (1010.7 ± 647.8 vs. 617.6 ± 315.8, p = 0.0001) and oxalate (28.21 ± 17.65 vs. 22.11 ± 16.49, p = 0.045) levels were significantly lower in osteopenia-osteoporosis patients than in controls, with no significant difference in calcium (187.3 ± 106.9 vs. 207.06 ± 98.12, p = 0.27) or uric acid (540.7 ± 186.2 vs. 511.9 ± 167.06, p = 0.35) levels. Patients with osteopenia-osteoporosis had significantly higher levels of lithogenic risk factors associated with bone remodeling, including significantly increased ß-crosslaps and osteocalcin values and higher ß-crosslaps/osteocalcin ratios. CONCLUSION: Patients with osteopenia-osteoporosis without nephrolithiasis showed phosphocalcic metabolism disorders as well as lower urinary citrate and higher ß-crosslaps/osteocalcin and fasting calcium/creatinine ratios, which would increase the risk of nephrolithiasis. Hence, prospective studies are warranted to evaluate the long-term risks.
Assuntos
Remodelação Óssea , Osteoporose/sangue , Osteoporose/urina , Absorciometria de Fóton , Adulto , Fosfatase Alcalina/sangue , Biomarcadores/sangue , Biomarcadores/urina , Densidade Óssea , Cálcio/sangue , Cálcio/urina , Estudos de Casos e Controles , Ácido Cítrico/urina , Colágeno/urina , Estudos Transversais , Jejum , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nefrolitíase/sangue , Nefrolitíase/urina , Osteocalcina/urina , Osteoporose/diagnóstico por imagem , Ácido Oxálico/urina , Hormônio Paratireóideo/sangue , Fragmentos de Peptídeos/urina , Fatores de Risco , Ácido Úrico/urinaRESUMO
A group of 68 premenopausal women participated in a controlled 12 month exercise program. Two groups were matched according to age, body size (body mass index), and typical activity level. Data collection included bone mineral density (BMD) of the lumbar spine with dual-photon absorptiometry and of the os calcis with single-photon absorptiometry, lean body mass, urinary calcium/creatinine, and urinary gamma-carboxyglutamic acid (Gla). Subjects were given a daily 500 mg supplement of elemental calcium. There was no significant difference between groups in terms of diet, in urinary calcium/creatinine or Gla, or in lean body mass. The weight lifting group had a nonsignificant increase in mean lumbar BMD of 0.81% and the control group exhibited a nonsignificant decrease of 0.5%. However, a paired t-test revealed a significant change in the means in either group or as matched pairs. The relatively small change seen as a result of this modified Nautilus exercise program may prevent moderate weight lifting from being a practical answer for osteoporosis, even in a highly motivated population.
Assuntos
Densidade Óssea/fisiologia , Levantamento de Peso , Adulto , Cálcio/urina , Creatinina/urina , Feminino , Humanos , Pessoa de Meia-Idade , Osteocalcina/urinaRESUMO
We have isolated and characterized human osteocalcin (OC) fragments from pubertal urine. The fragments were isolated by immunoaffinity chromatography based on monoclonal antibody 6F9 and further purified by reverse phase chromatography. The major isolated forms, which were detectable with two-site immunofluorometric assays for serum OC, span residues 6-30 and 7-30 as determined by mass spectrometry and N-terminal amino acid sequencing. Full-length OC was not detectable in the supernatant fraction of urine but could be extracted with guanidinium hydrochloride from the sediment of urine samples. Urine samples from subjects with different menopausal status were measured by two different two-site assays. Urine OC (uOC) concentrations were 12- to 16-fold higher in the pubertal group than in the adult group. Also, the uOC concentration in a postmenopausal group was significantly higher than in a premenopausal group. The difference was 125% and 75% (values for p < 0.0001), respectively, when measured with the two assays. uOC concentrations in postmenopausal subjects on hormone replacement therapy were indistinguishable from the premenopausal subjects. The fact that uOC can be measured by a noncompetetive two-site assay design offers improved analytical sensitivity. Urine as the sample matrix is also especially interesting because the predominant markers of bone resorption, collagen type I peptides or cross-links, are performed on urine samples. Our results from the technical validation of two-site assays for uOC and from applying these to human pubertal and pre- and postmenopausal samples calls for more extensive clinical validation.